Completed PHASE3 INTERVENTIONAL NCT00197080

Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome

A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome

Sponsor: GlaxoSmithKline

Conditions Restless Legs Syndrome

Interventions Ropinirole Extended Release (XR)

Updated 6 times since 2017 Last updated: Sep 22, 2016 Started: Jun 30, 2005 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Restless Legs Syndrome, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ajax, Canada , Alabaster, United States , Albany, United States , Albuquerque, United States , Alexandria, United States , Anaheim, United States , Atlanta, United States , Austell, United States , Baton Rouge, United States , Bellingham, United States and 57 more locations